Investigational Studies

Revive Therapeutics submitted an application to the FDA for an orphan drug designation to its CBD treatment of hepatic ischemia and reperfusion injury during liver transplantation. Revive Therapeutics (TSXV:RVV) submitted an application to the US Food and Drug Administration (FDA) for an orphan drug designation to its cannabidiol (CBD) treatment of hepatic ischemia and reperfusion injury (IRI) during liver […]

by

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) (“Reviveâ€� or the “Companyâ€�), a specialty medical cannabis company, today announced that it has submitted an application to the U.S. Food and Drug Administration (“FDAâ€�) seeking orphan drug designation of cannabidiol (“CBDâ€�) for the treatment of hepatic ischemia and reperfusion injury […]

by

On June 25th, 2018, the U.S. Food and Drug Administration (FDA) approved the drug, Epidiolex, for the treatment of seizures associated with two rare forms of epilepsy, Dravet syndrome, and Lennox-Gastaut syndrome[1]. The active ingredient in Epidiolex, cannabidiol (CBD), is a chemical compound found in marijuana, but is not associated with the euphoria caused by […]

by

In recent years, we have seen some extraordinary results related to the use of CBD for treatment and therapy in a variety of different health conditions. However, there is one particular condition that perhaps sits atop the pyramid as far as the sense of dramatic relief related to CBD use:  Dravet Syndrome. Understanding Dravet Syndrome […]

by

In recent years, we have seen some extraordinary results related to the use of CBD for treatment and therapy in a variety of different health conditions. However, there is one particular condition that perhaps sits atop the pyramid as far as the sense of dramatic relief related to CBD use:  Dravet Syndrome. Understanding Dravet Syndrome […]

by

Opdivo, Yervoy Combination For Colorectal Cancer Cases The combination of nivolumab (Opdivo) and ipilimumab (Yervoy), both made by Bristol-Myers Squibb, has received FDA accelerated approval for the treatment of adult and pediatric patients 12 years of age and older with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer (mCRC) that has progressed following […]

by

Opdivo, Yervoy Combination For Colorectal Cancer Cases The combination of nivolumab (Opdivo) and ipilimumab (Yervoy), both made by Bristol-Myers Squibb, has received FDA accelerated approval for the treatment of adult and pediatric patients 12 years of age and older with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer (mCRC) that has progressed following […]

by

Opdivo, Yervoy Combination For Colorectal Cancer Cases The combination of nivolumab (Opdivo) and ipilimumab (Yervoy), both made by Bristol-Myers Squibb, has received FDA accelerated approval for the treatment of adult and pediatric patients 12 years of age and older with microsatellite instability high or mismatch repair deficient metastatic colorectal cancer (mCRC) that has progressed following […]

by

Zogenix, Inc.  announced successful completion of its second confirmatory phase III study (Study 1504) evaluating its pipeline candidate, ZX008 (low-dose fenfluramine hydrochloride), for treating Dravet syndrome, a type of epilepsy in children and young adults. The data was consistent with the positive results observed in the first pivotal phase III study in reducing monthly convulsive […]

The U.S. Food and Drug Administration on Monday approved the country’s first drug derived from marijuana, a medication that treats two rare and devastating forms of epilepsy. The drug, produced by GW Pharmaceuticals plc (Nasdaq: GWPH) and called Epidiolex®, is made from cannabidiol (CBD), a component of marijuana that does not give users a high. […]